MedAdvisor Limited, together with its subsidiaries, develops and delivers software for personal medication management in Australia, the United States, the United Kingdom, and Asia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.33|
|52 Week High||AU$0.23|
|52 Week Low||AU$0.42|
|1 Month Change||11.86%|
|3 Month Change||8.20%|
|1 Year Change||-18.52%|
|3 Year Change||20.88%|
|5 Year Change||17.86%|
|Change since IPO||-9.34%|
Recent News & Updates
Is MedAdvisor (ASX:MDR) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|MDR||AU Healthcare Services||AU Market|
Return vs Industry: MDR underperformed the Australian Healthcare Services industry which returned 39.9% over the past year.
Return vs Market: MDR underperformed the Australian Market which returned 21.1% over the past year.
Stable Share Price: MDR is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: MDR's weekly volatility (11%) has been stable over the past year.
About the Company
MedAdvisor Limited, together with its subsidiaries, develops and delivers software for personal medication management in Australia, the United States, the United Kingdom, and Asia. The company provides MedAdvisor, a medication and adherence platform that focuses on improving health outcomes by connecting health professionals with their patients using technology and enhancing medication adherence through health programs using mobile and web apps. MedAdvisor Limited was incorporated in 2010 and is headquartered in Camberwell, Australia.
MedAdvisor Fundamentals Summary
|MDR fundamental statistics|
Is MDR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MDR income statement (TTM)|
|Cost of Revenue||AU$40.91m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.037|
|Net Profit Margin||-35.98%|
How did MDR perform over the long term?See historical performance and comparison
Is MedAdvisor undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MDR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MDR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MDR is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.
PE vs Market: MDR is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MDR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MDR is good value based on its PB Ratio (2.6x) compared to the AU Healthcare Services industry average (4.2x).
How is MedAdvisor forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MedAdvisor has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has MedAdvisor performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDR is currently unprofitable.
Growing Profit Margin: MDR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDR is unprofitable, and losses have increased over the past 5 years at a rate of 30.9% per year.
Accelerating Growth: Unable to compare MDR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).
Return on Equity
High ROE: MDR has a negative Return on Equity (-29.42%), as it is currently unprofitable.
How is MedAdvisor's financial position?
Financial Position Analysis
Short Term Liabilities: MDR's short term assets (A$21.3M) do not cover its short term liabilities (A$23.3M).
Long Term Liabilities: MDR's short term assets (A$21.3M) exceed its long term liabilities (A$8.8M).
Debt to Equity History and Analysis
Debt Level: MDR's debt to equity ratio (13.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MDR's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MDR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27% each year
What is MedAdvisor current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MDR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MDR's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Robert Read, BComm(Mgt), BA(Psych), GAICD., has been the Chief Executive Officer of MedAdvisor Limited since November 12, 2015 and also serves as its Managing Director. Mr. Read served as Managing Dire...
CEO Compensation Analysis
Compensation vs Market: Robert's total compensation ($USD553.64K) is above average for companies of similar size in the Australian market ($USD303.55K).
Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.
Experienced Management: MDR's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: MDR's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.2%.
MedAdvisor Limited's employee growth, exchange listings and data sources
- Name: MedAdvisor Limited
- Ticker: MDR
- Exchange: ASX
- Founded: 2010
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$124.567m
- Shares outstanding: 377.48m
- Website: https://www.medadvisor.com.au
- MedAdvisor Limited
- 971 Burke Road
- Level 2
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 18:20|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.